From the Department of Plastic Surgery, Virginia Commonwealth University-Inova Branch, National Center for Plastic Surgery.
Plast Reconstr Surg. 2021 May 1;147(5S):44S-50S. doi: 10.1097/PRS.0000000000008045.
Current controversies surrounding breast implants are focused not only on the implant but also on the capsule. There has been tremendous discussion regarding how much of the capsule, if any, should be removed during explantation for benign conditions. The appearance of benign capsules is highly variable ranging from a thin membrane to densely fibrotic with calcifications. The options for capsulectomy include none, partial, complete, complete-intact, and en bloc. Some patients are requesting en bloc capsulectomy even in the absence of anaplastic large cell lymphoma; however, the scientific evidence only supports this for patients with capsular malignancies. The purpose of this article is to review the old and new evidence to answer the question regarding how much capsule should be removed during explantation for benign conditions.
目前围绕着乳房植入物的争议不仅集中在植入物本身,也集中在胶囊上。对于良性疾病在取出植入物时,应切除多少胶囊(如果有的话),存在着巨大的争议。良性胶囊的外观变化多样,从薄的膜到致密纤维化伴钙化。囊切除术的选择包括不切除、部分切除、完全切除、完整保留和整块切除。一些患者即使没有间变性大细胞淋巴瘤也要求整块切除胶囊,但科学证据仅支持对患有囊状恶性肿瘤的患者进行这种手术。本文的目的是回顾旧的和新的证据,以回答在良性疾病取出植入物时应切除多少胶囊的问题。